相关实验视频

Updated: Jan 15, 2026

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

对瘤免疫微环境的比较分析,介于胸腺瘤和胸腺癌之间

Shoko Sonobe Shimamura¹, Takehito Shukuya², Makiko Yamashita³

¹Division of Clinical Chemotherapy, Cancer Chemotherapy Center, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Lung cancer (Amsterdam, Netherlands)

|October 10, 2025

概括

胸膜上皮瘤 (TETs) 中的瘤免疫微环境 (TIME) 影响预后. 瘤区域中较高的CD4+,CD8+T细胞和CD68+细胞表明预后良好,而侧膜中的B细胞则表明前景不佳.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
病理学病理学病理学

背景情况:

胸膜上皮瘤 (TETs),通常与自身免疫综合征,如肌痛性硬化症 (MG) 相关,有一个研究不足的瘤免疫微环境 (TIME).
了解 TIME 对于改善 TET 免疫检查点抑制剂疗效至关重要.
这项研究调查了TIME在胸腺瘤和胸腺癌 (TC) 中及其与MG的关联.

研究的目的:

为了分析瘤免疫微环境 (TIME) 在胸膜上皮瘤 (TETs).
为了确定TET亚型 (胸腺瘤和胸腺癌) 中的TIME成分的预后意义.
探索胸腺瘤和骨髓灰质炎 (MG) 的免疫微环境之间的关系.

主要方法:

在157个手术切除的TET标本中分析免疫细胞密度,使用多重光免疫组织化学染色.
胸腺瘤和胸腺癌 (TC) 之间的TIME特征的比较.
评估特定免疫细胞种群,MG状态和患者预后之间的相关性.

主要成果:

胸腺瘤 (145名患者) 的T细胞患病率高于TC细胞 (12名患者).
在瘤区域内增加的CD4+,CD8+T细胞和CD68+细胞与良好的预后相关.
脑管区域中CD20+CD79a-B细胞增加与胸腺瘤的预后不佳有关,而在MG胸腺瘤中更高.

结论:

时间显著影响了胸膜上皮瘤 (TETs) 的预后.
瘤区域的特定免疫细胞透,包括CD4+ T细胞,CD8+ T细胞和CD68+细胞,是有利的预后指标.
流体B细胞的存在表明胸腺瘤的预后不佳,突出了潜在的治疗点.

关键词:

多重光免疫组织化学学骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.预测预后预测预测胸膜瘤是一个瘤.

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.